Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease

Journal of Inherited Metabolic Disease

Volumn 35, Issue 6, 2012, Pages 1107-1117

  Marchesan, D ^a   Cox, T M ^a   Deegan, P B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; EUROPIUM; SOMATOMEDIN B RECEPTOR;

ARTICLE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG UPTAKE; ENDOTHELIUM CELL; FABRY DISEASE; FIBROBLAST; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LYSOSOME; PRECIPITATION; PROTEIN EXPRESSION;

ALPHA-GALACTOSIDASE; CELL LINE; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; ENDOTHELIAL CELLS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FIBROBLASTS; HUMANS; ISOENZYMES; LYSOSOMES; MICROSCOPY, CONFOCAL; MODELS, BIOLOGICAL; RECEPTOR, IGF TYPE 2; RECOMBINANT PROTEINS;

EID: 84867847128     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9472-3     Document Type: Article

References (70)

1. Aden DP, Fogel A, et al.(1979) Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282(5739):615-616
2. Aerts JM, Groener JE, et al.(2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 105(8):2812-2817
3. Barbey F, Brakch N, et al.(2006) Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol 26(4):839-844
4. Berger HU, et al.(1974) Methods of enzymatic analysis. Academic Press, New York, pp 495-496
5. Bishop DF, Desnick RJ (1981) Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms. J Biol Chem 256(3):1307-1316
6. Blom D, Speijer D, et al.(2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 72(1):23-31
7. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224(Pt 3):213-232
8. Boutouyrie P, Laurent S, et al.(2002) Arterial remodelling in Fabry disease. Acta Paediatr Suppl 91(439):62-66
9. Breunig F, Wanner C (2008) Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J Nephrol 21(1):32-37
10. Christensen EI, Zhou Q, et al.(2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18(3):698-706
11. Clarke JT (1981) The glycosphingolipids of human plasma lipoproteins. Can J Biochem 59(6):412-417
12. Clarke JT (2007) Narrative review: Fabry disease. Ann Intern Med 146(6):425-433
13. Clarke JT, Stoltz JM, et al.(1976) Neutral glycosphingolipids of serum lipoproteins in Fabry's disease. Biochim Biophys Acta 431(2):317-325
14. Clarke JT, Stoltz JM, et al.(1980) Stability of plasma low density lipoprotein with abnormal glycolipid composition from patients with Fabry's disease. Atherosclerosis 35(2):155-163
15. Dahms NM, Hancock MK (2002) P-type lectins. Biochim Biophys Acta 1572(2-3):317-340
16. Darlington GJ, Kelly JH, et al.(1987) Growth and hepatospecific gene expression of human hepatoma cells in a defined medium. Vitro Cell Dev Biol 23(5):349-354
17. Deegan PB, Baehner AF, et al.(2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43(4):347-352
18. DeLisser HM, Yan HC, et al.(1993) Platelet/endothelial cell adhesion molecule-1 (CD31)-mediated cellular aggregation involves cell surface glycosaminoglycans. J Biol Chem 268(21):16037-16046
19. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill, 8th ed. Vol. 3:3733-74
20. Desnick RJ (2001) Enzyme replacement and beyond. J Inherit Metab Dis 24(2):251-265
21. Elleder M (1985) Fabry's disease: absence of storage as a feature of liver sinus endothelium. Acta Histochem 77(1):33-36
22. Elleder M (2003) Sequelae of storage in Fabry disease - pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92(443):46-53, discussion 45
23. Elleder M, Ledvinova J, et al.(1990) An atypical ultrastructural pattern in Fabry's disease: a study on its nature and incidence in 7 cases. Ultrastruct Pathol 14(6):467-474
24. Elsea SH, Lucas RE (2002) The mousetrap: what we can learn when the mouse model does not mimic the human disease. ILAR J 43(2):66-79
25. Eng CM, Guffon N, et al.(2001) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345(1):9-16
26. Fellgiebel A, Muller MJ, et al.(2006) CNS manifestations of Fabry's disease. Lancet Neurol 5(9):791-795
27. Ghosh P, Dahms NM, et al.(2003) Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 4(3):202-212
28. Ginsberg L, Manara R, et al.(2006) Magnetic resonance imaging changes in Fabry disease. Acta Paediatr Suppl 95(451):57-62
29. Grabowski GA, Hopkin RJ (2003) Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Annu Rev Genomics Hum Genet 4:403-436
30. Graham J, Ford T, et al.(1994) The preparation of subcellular organelles from mouse liver in self-generated gradients of iodixanol. Anal Biochem 220(2):367-373
31. Grewal RP (1994) Stroke in Fabry's disease. J Neurol 241(3):153-156
32. Gubler MC, Lenoir G, et al.(1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13(3):223-235
33. Hasholt L, Wandall A, et al.(1988) Enzyme replacement in Fabry endothelial cells and fibroblasts: uptake experiments and electron microscopical studies. Clin Genet 33(5):360-371
34. Haslett C, Guthrie LA, et al.(1985) Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 119(1):101-110
35. Hilz MJ, Kolodny EH, et al.(2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251(5):564-570
36. Kalliokoski RJ, Kalliokoski KK, et al.(2006) Structural and functional changes in peripheral vasculature of Fabry patients. J Inherit Metab Dis 29(5):660-666
37. Karen JK, Hale EK, et al.(2005) Angiokeratoma corporis diffusum (Fabry disease). Dermatol Online J 11(4):8
38. Keller H, Niggli V (1995) Effects of cytochalasin D on shape and fluid pinocytosis in human neutrophils as related to cytoskeletal changes (actin, alpha-actinin and microtubules). Eur J Cell Biol 66(2):157-164
39. Keslova-Veselikova J, Hulkova H, et al.(2008) Replacement of alpha-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. Virchows Arch 452(6):651-665
40. Knowles BB, Howe CC, et al.(1980) Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209(4455):497-499
41. Lee K, Jin X, et al.(2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13(4):305-313
42. Li Q, Lau A, et al.(2004) A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J Neurosci 24(16):4070-4081
43. Lin Y, Weisdorf D, Solovey A, Hebbel RP (2000a) Origins of circulating endothelial outgrowth from blood. J Clin Invest 105:71-77
44. Lin Y, Weisdorf DJ, et al.(2000b) Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 105(1):71-77
45. Lin Y, Chang L, et al.(2002) Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 99(2):457-462
46. Mayes JS, Scheerer JB, et al.(1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112(2):247-251
47. Medin JA, Tudor M, et al.(1996) Correction in trans for Fabry disease: expression, secretion and uptake of alpha-galactosidase A in patient-derived cells driven by a high-titer recombinant retroviral vector. Proc Natl Acad Sci U S A 93(15):7917-7922
48. Moore DF, Scott LT, et al.(2001) Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 104(13):1506-1512
49. Moore DF, Kaneski CR, et al.(2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257(1-2):258-263
50. Nguyen TT, Gin T, et al.(2005) Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin Experiment Ophthalmol 33(2):164-168
51. Parkkila S, Parkkila AK, et al.(1993) Competitive time-resolved immunofluorometric assay for quantifying carbonic anhydrase VI in saliva. Clin Chem 39(10):2154-2157
52. Prabakaran T, Nielsen R, et al.(2011) Receptor-Mediated Endocytosis of alpha-Galactosidase A in Human Podocytes in Fabry Disease. PLoS One 6(9):e25065
53. Rafii S, Lyden D (2003) Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9(6):702-712
54. Sakuraba H, Murata-Ohsawa M, et al.(2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51(3):180-188
55. Schiffmann R, Murray GJ, et al.(2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97(1):365-370
56. Schiffmann R, Kopp JB, et al.(2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Jama 285(21):2743-2749
57. Schiffmann R, Rapkiewicz A, et al.(2006) Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448(3):337-343
58. Shen JS, Meng XL, et al.(2007) Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 92(1-2):137-144
59. Sheppard MN, Cane P, et al.(2010) A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 19(5):293-301
60. Sleat DE, Wang Y, et al.(2006) Identification and validation of mannose 6-phosphate glycoproteins in human plasma reveal a wide range of lysosomal and non-lysosomal proteins. Mol Cell Proteomics 5(10):1942-1956
61. Sodi A, Ioannidis AS, et al.(2007) Ocular manifestations of Fabry's disease: data from the Fabry outcome survey. Br J Ophthalmol 91(2):210-214
62. Speert DP, Silverstein SC (1985) Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. J Leukoc Biol 38(5):655-658
63. Synnes M, Prydz K, et al.(1999) Fluid phase endocytosis and galactosyl receptor-mediated endocytosis employ different early endosomes. Biochim Biophys Acta 1421(2):317-328
64. Takamatsu S, Fukuta K, et al.(2003) Monitoring biodistribution of glycoproteins with modified sugar chains. Biochim Biophys Acta 1622(3):179-191
65. Thurberg BL, Randolph Byers H, et al.(2004) Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. J Invest Dermatol 122(4):900-908
66. Wagner SJ, Myrup AC (2005) Toward closed-system culture of blood origin endothelial cells. Transfusion 45(7):1201-1207
67. Wang CH, Cherng WJ, et al.(2008) Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 28(1):54-60
68. Wilcox WR (2004) Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr 144(5 Suppl):S3-S14
69. Wilcox WR, Banikazemi M, et al.(2004) Long-term safety and efficacy of enzyme replacement therapyfor fabry disease. Am J Hum Genet 75(1):65-74
70. Wu X, Robinson CE, et al.(1995) Cloning and characterization of the murine activin receptor like kinase-1 (ALK-1) homolog. Biochem Biophys Res Commun 216(1):78-83